Member Info for peterobert

Is that the results will be out in the beginning of May.

They will show the increase in commercializing during 2023,

and show more movement towards profit.

The impression I get is that great strides have been made,

and will show how undervalued the SP has been, and show

that a re-rating is justified. Am thinking of 20p initially.

Also expect a larger company may move to take-over.

imho- dyor

Https://www.britishbulls.com/SignalPage.aspx?lang=en&Ticker=dest.L

Https://www.britishbulls.com/SignalPage.aspx?lang=en&Ticker=gsf.L

Https://www.britishbulls.com/SignalPage.aspx?lang=en&Ticker=groc.L

One can imagine the impact on revenue of Ondine as Steriwave gains recognition in hospitals throughout the world which adopt it as the preferred method to achieve huge reductions in fatalities

The resultant share price achievement, which is currently tiny, would be significant

Thank you for your note, Peter. We recognize that there are questions and are working to address this issue.

Https://www.britishbulls.com/SignalPage.aspx?lang=en&Ticker=obi.L

6.53-6.8p current low price

Entry into ICU market expands revenue potential

Following interest from Canadian Hospitals, Ondine prepares to enter the Intensive Care Unit (ICU) market

· Treatment of patients in ICUs would significantly expand Ondine's

potential market opportunity.

· Hundreds of thousands of patients are admitted to the ICU every year

in Canada alone, with an average stay of over four days.

6.655-7.08 current price

in my opinion this has to be a steal

Ondine Biomedical Inc on Monday reported that a study undertaken at the Mazankowski Alberta Heart Institute demonstrated a 32% reduction in cardiac surgical site infections through the use of its Steriwave product as a replacement for the antibiotic Mupirocin.

This comes after Steriwave was implemented on a pilot basis as a replacement for Mupirocin in June last year, the Vancouver-based life sciences company said.

Steriwave is a light-activated antimicrobial which employs patented nasal photodisinfection technology to eliminate bacteria, fungi and viruses located on human tissues.

According to Ondine, SSIs are "one of the most significant complications in cardiac surgery patients and are strongly associated with poorer prognosis".

Just last week, Ondine announced that Steriwave had been approved by HCA Healthcare UK for use in its healthcare facilities.

Shares in Ondine were up 1.0% at 7.57 pence each in London on Monday afternoon.

One can imagine the impact on revenue as it gains total acceptance as the way to achieve huge reductions in fatalities.

The resultant revenue of Ondine steriwave would be huge as hospitals throughout the world use it as the preferred method.

Commercialization is the key

My buy yesterday was shown as a sell

Https://ondinebio.com/solutions/steriwave-healthcare/

Their shares are currently Cheap as Chips

imho - dyor

Https://ondinebio.com/solutions/steriwave-healthcare/

Listen to the short video

Light-activated antimicrobial that does not generate antimicrobial resistance (AMR) approved for use in healthcare facilities operated by leading private healthcare provider HCA Healthcare UK Leading private healthcare provider, HCA Healthcare UK, has approved the Steriwave® light-activated antimicrobial developed by Ondine Biomedical Inc. (LON:OBI) for use in its healthcare facilities to prevent healthcare-associated infections (HAIs) and reduce the use of antibiotics. HCA Healthcare is the largest private healthcare provider in the world, and one of the leading private healthcare providers in the UK, where it operates over 30 healthcare facilities.

Antimicrobial resistance (AMR) is a growing concern for healthcare providers around the world, particularly in the prevention and treatment of HAIs. Steriwave is a light-activated antimicrobial with a distinct mechanism of action from traditional antibiotics, allowing it to be used without fear of generating AMR. Its broad-spectrum efficacy destroys bacteria, viruses, and fungi in a single, 5-minute treatment.

Steriwave has already been successfully used in a small patient population in HCA Healthcare UK hospitals, but this approval will allow additional hospitals and healthcare facilities to adopt the technology more widely at the discretion of the clinician.

Professor Claire Hopkins, Professor of Rhinology at King's College London and Consultant ENT Surgeon at Guy's & St Thomas' NHS Foundation Trust and London Bridge Hospital, has used Steriwave routinely to nasally decolonise her endoscopic sinus surgery patients at HCA Healthcare UK's London Bridge Hospital since 2021. A retrospective study showed that using Steriwave in endoscopic sinus surgery patients led to antibiotic use across all her patients dropping from 22% to less than 5% – a 77% reduction.

Professor Hopkins commented: "I was amazed that studies show that by treating the nose you can reduce spinal surgical site infections – so it seemed an ideal way to reduce the risk of post-operative infection after nasal surgery. I have seen a significant reduction in post-operative infections requiring antibiotics, which is good for the patients, reducing the risk of antibiotic-related side effects, and important to help prevent ever-increasing antibiotic resistance. It needs formal controlled studies to further evaluate the effectiveness, but I am impressed with the difference that I have seen in my practice."

Interview with Professor Hopkins: Steriwave prevents sinonasal SSIs (https://ondinebio.com/media/steriwave-prevents-sinonasal-ssis/?portfolioCats=68)

Carolyn Cross, Ondine Biomedical CEO, commented: "We are delighted that Steriwave has now been authorized for use across HCA Healthcare UK's healthcare facilities. We are already working closely with HCA Healthcare in the US on our US Phase 3 trial and the FDA regulatory submission for Steriwave, so it is fantastic to be getting such good support from them in the UK as we

Patients in West Yorkshire have become the first in the country to access a new pre-surgery laser treatment, following a successful trial.

Mid Yorkshire Teaching NHS Trust has started to roll out Steriwave on those coming in for hip and knee surgery.

The treatment involves a probe shining a red light into patients' nostrils to kill off bacteria which cause surgical site infections.

Dr Stuart Bond called it an "important new technology".

"We are very excited to be the first Trust to be giving patients access to this important new technology which kills viruses, bacteria, and fungi with a five-minute treatment," Dr Bond, a consultant antimicrobial pharmacist and director of innovation, said.

The treatment was rolled out following a successful trial at Pontefract Hospital last year, with the aim of helping to prevent patients getting infections during surgery.

The NHS has previously said it hopes it could be an alternative to nasal antibiotics, which are currently given to patients before their surgery to prevent infections such as MRSA.

Carolyn Cross, chief executive officer at Ondine Biomedical, said: "We are delighted the Trust has adopted Steriwave, particularly as the NHS is seen around the world as a leader in antibiotic stewardship in response to the growing threat of antimicrobial resistance."

Presentational grey line

Follow BBC Yorkshire on Facebook, X (formerly T

7.03-7.20p

current price

so just bought more

Https://www.bbc.co.uk/news/uk-england-leeds-68772991